Company adjusts earnings expectations due to ImmunoGen deal

  • AbbVie’s stock falls 0.5% after lowering Q1 guidance
  • Lowered guidance due to dilutive impact of ImmunoGen deal
  • First-quarter per-share earnings expected to range from $2.26 to $2.30
  • Full-year adjusted EPS expected to be $11.05 to $11.25

AbbVie Inc.’s stock fell 0.5% early Monday after the company lowered its first-quarter guidance. The adjustment reflects the dilutive impact of the acquisition of ImmunoGen. First-quarter per-share earnings are now expected to range from $2.26 to $2.30, down from the previous guidance of $2.30 to $2.34. This includes a 4 cent per share dilutive impact from the Immunogen deal. AbbVie also announced its full-year adjusted EPS of $11.05 to $11.25, which includes a 42 cent per share dilutive impact from the ImmunoGen deal and the pending close of Cerevel Therapeutics Holdings Inc. The stock has gained 14.5% in the last 12 months.

Public Companies: AbbVie Inc. (ABBV), ImmunoGen (null), Cerevel Therapeutics Holdings Inc. (CERE)
Private Companies:
Key People:

Track all markets on TradingView

Factuality Level: 8
Justification: The article provides specific information about AbbVie Inc.’s stock falling due to the dilutive impact of its acquisition of ImmunoGen. It includes details about the revised first-quarter guidance and the impact on earnings. The article also mentions AbbVie’s plan to acquire Cerevel Therapeutics Holdings Inc. and provides information about the stock’s performance in the last 12 months. Overall, the article presents factual information without any obvious bias or misleading content.

Noise Level: 3
Justification: The article provides relevant information about AbbVie Inc.’s stock and its lowered first-quarter guidance due to the dilutive impact of its acquisition of ImmunoGen. It also mentions the pending close of Cerevel Therapeutics Holdings Inc. and provides details about the company’s stock performance. However, the article lacks in-depth analysis, scientific rigor, and actionable insights.

Financial Relevance: Yes
Financial Markets Impacted: AbbVie Inc. and ImmunoGen

Presence of Extreme Event: No
Nature of Extreme Event: No
Impact Rating of the Extreme Event: No
Justification: The article pertains to the financial performance of AbbVie Inc. and its stock. It discusses the dilutive impact of the acquisition of ImmunoGen on AbbVie’s first-quarter guidance and full-year adjusted EPS. There is no mention of an extreme event.

Reported publicly: www.marketwatch.com